Barley pest defensin source modified antibacterial peptide and application thereof
By adding a repeat sequence design and modification of antimicrobial peptides with specific amino acid combinations in insect defensin from barley insects, the problem of antibiotic resistance to MRSA is solved, and the efficient bactericidal and low toxicity of drug-resistant bacteria is achieved, with broad-spectrum antibacterial and Characteristics of self-assembled nanofiber webs.
Patent Information
- Application Number
- CN202410151840.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-02-02
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-02-02
AI Technical Summary
The existing antibiotics have prominent resistance to bacteria such as methicillin-resistant Staphylococcus aureus (MRSA), and the antibacterial efficiency of natural barley defensins is relatively low, especially for MRSA.
By adding continuous 2-3 repeat sequences of tryptophan, leucine or arginine combinations at both ends of the specific amino acid fragment of the insect defensin Z-d14CFR in the barley source, a series of modified antimicrobial peptides were designed to increase the structure. Symmetry and stability were synthesized and identified by solid phase synthesis and mass spectrometry, and polypeptides such as Z(WR)2, Z(WR)3, etc. were obtained, and antibacterial activity determination and cytotoxicity determination were performed.
The modified antibacterial peptide has strong antibacterial activity on common resistant bacteria such as E. coli, Staphylococcus aureus, and some of them show excellent antibacterial properties on MRSA, and has almost no effect on cytotoxicity and hemolyticity. It can self-assemble and form nanometers. The fiber mesh adheres to bacteria and destroys bacterial membranes, exerting antibacterial effects.
Smart Images

Figure CN119039392A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and in particular relates to barley worm defensin-derived modified antimicrobial peptides and applications thereof. Background Art
[0002] Antibiotics were once considered the most effective means to combat bacterial infections. However, with the use of antibiotics, bacterial resistance has become increasingly prominent, including Escherichia coli, Staphylococcus aureus, Klebsiella and other bacteria. In particular, the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in hospitals has posed a challenge to preventing secondary bacterial infections caused by surgery, etc. In addition, with the use of vancomycin, MRSA's sensitivity has gradually decreased, and it is hindered by systems such as biofilms, making it more difficult for antibiotics to penetrate and kill bacteria.
[0003] Antimicrobial peptides (AMPs) are a class of short-chain polypeptides with positive charges. As an important defense mechanism of organisms, they are widely distributed in animals and plants. Their antibacterial effect mainly comes from the direct destruction of bacterial membranes. This antibacterial effect makes it difficult for bacteria to develop resistance to antimicrobial peptides. It is an important means to combat bacterial resistance. Although insect antimicrobial peptides, mainly barley worm defensins, have advantages such as good biosafety, they have low antibacterial efficiency under natural sequences and have limited effects on Gram-positive bacteria, such as MRSA. Therefore, the development of modified antimicrobial peptides with more efficient and broad-spectrum bactericidal functions based on barley worm defensins is an effective means to solve this problem. Summary of the invention
[0004] The purpose of the present invention is to provide a barley worm defensin-derived modified antimicrobial peptide and its application.
[0005] The invention increases the structural symmetry and structural stability by adding 2-3 pairs of continuous repeating sequences of tryptophan (W) or leucine (L), arginine (R) or lysine (K) combination at both ends of the 5-11 amino acid fragment (CNSKSFC) of the insect defensin Z-d14CFR from barleyworm, and then synthesizes a series of modified antimicrobial peptides by solid phase synthesis, identifies the polypeptide by mass spectrometry and purifies it by high performance liquid chromatography, and then performs antibacterial activity determination, cytotoxicity determination and self-assembly ability determination, and finally names them as modified antimicrobial peptides Z(WR)2, Z(WR)3, Z(WK)(WR), Z(WK)2, Z(WK)3, Z(LR)2, Z(LR)3, Z(LK)(LR), Z(LK)2 and Z(LK)3.
[0006] In order to achieve the purpose of the present invention, in the first aspect, the present invention provides a barley worm defensin-derived modified antimicrobial peptide, wherein the antimicrobial peptide is Z(WR)2, Z(WR)3, Z(WK)(WR), Z(WK)2, Z(WK)3, Z(LR)2, Z(LR)3, Z(LK)(LR), Z(LK)2 or Z(LK)3 (SEQ ID NO: 1-10):
[0007] Z(WR)2: WRWRCNSKSFCRWRW-NH2;
[0008] Z(WR)3: WRWRWRCNSKSFCRWRWRW-NH2;
[0009] Z(WK)(WR):WRWKCNSKSFCKWRW-NH2;
[0010] Z(WK)2:WKWKCNSKSFCKWKW-NH2;
[0011] Z(WK)3:WKWKWKCNSKSFCKWKWKW-NH2;
[0012] Z(LR)2:LKLKCNSKSFCKLKL-NH2;
[0013] Z(LR)3:LKLKLKCNSKSFCKLKLKL-NH2;
[0014] Z(LK)(LR):LRLKCNSKSFCKLRL-NH2;
[0015] Z(LK)2:LRLRCNSKSFCRLRL-NH2;
[0016] Z(LK)3: LLRLRCNSKSFCRLRLRL-NH2.
[0017] Furthermore, the molecular formula of the modified antimicrobial peptide is shown in formula (I) to (X):
[0018]
[0019]
[0020] In a second aspect, the present invention provides a nucleic acid molecule encoding the antimicrobial peptide.
[0021] In a third aspect, the present invention provides biological materials containing the nucleic acid molecule, wherein the biological materials include but are not limited to recombinant DNA, expression cassettes, transposons, plasmid vectors, viral vectors, engineered bacteria or transgenic cell lines.
[0022] In a fourth aspect, the present invention provides a recombinant microorganism, wherein the recombinant microorganism expresses the antimicrobial peptide.
[0023] In a fifth aspect, the present invention provides any of the following applications of the antimicrobial peptide:
[0024] 1) Used to inhibit bacteria;
[0025] 2) Used for preparing antibacterial agents;
[0026] 3) Used to prepare preservatives;
[0027] 4) Used for preparing antibacterial drugs.
[0028] The bacteria include Gram-negative bacteria and Gram-positive bacteria.
[0029] The Gram-negative bacteria are selected from Escherichia coli, Salmonella, Klebsiella, etc., such as Salmonella typhimurium and Klebsiella pneumoniae.
[0030] The Gram-positive bacteria are selected from Staphylococcus aureus, methicillin-resistant Staphylococcus aureus (MRSA), Streptococcus, etc., such as Streptococcus suis.
[0031] By means of the above technical solution, the present invention has at least the following advantages and beneficial effects:
[0032] The modified antimicrobial peptides provided by the present invention have strong antimicrobial activity against common drug-resistant bacteria such as Escherichia coli, Staphylococcus aureus, Klebsiella, etc., and some of the modified antimicrobial peptides have excellent antimicrobial properties against MRSA and its clinically isolated strains; they have almost no toxicity to macrophages, mammary epithelial cells, and renal epithelial cells, and are non-hemolytic to animal blood cells; the antimicrobial peptides can self-assemble to form nanofiber meshes to adhere to bacteria; in addition, the modified antimicrobial peptides mainly exert their antibacterial effects by destroying bacterial membranes, and have application potential in combating bacterial infections such as drug-resistant bacteria. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 This is a time-killing curve of the modified antimicrobial peptide in a preferred embodiment of the present invention.
[0034] Figure 2 This is a preferred embodiment of the present invention in which the cytotoxicity of the antimicrobial peptide is modified.
[0035] Figure 3 This is a graph showing the hemolytic activity test results of the modified antimicrobial peptide in a preferred embodiment of the present invention.
[0036] Figure 4 This is a diagram showing the bactericidal mechanism of the modified antimicrobial peptide against E. coli CAU201919 under a scanning electron microscope in a preferred embodiment of the present invention.
[0037] Figure 5 This is a diagram showing the bactericidal mechanism of the modified antimicrobial peptide against S. aureus ATCC33591 under a scanning electron microscope in a preferred embodiment of the present invention.
[0038] Figure 6 This is a picture of a nanofiber network formed by modifying antimicrobial peptides under a transmission electron microscope in a preferred embodiment of the present invention. DETAILED DESCRIPTION
[0039] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. Unless otherwise specified, the technical means used in the examples are conventional means well known to those skilled in the art, and the raw materials used are all commercially available products.
[0040] Example 1 Design and synthesis of modified antimicrobial peptides
[0041] By adding 2-3 pairs of continuous repeating sequences of tryptophan (W) or leucine (L), arginine (R) or lysine (K) at both ends of the 5-11 amino acid fragment of the insect defensin Z-d14CFR from barley worm, the structural symmetry and structural stability are increased, thereby designing modified antimicrobial peptides Z(WR)2, Z(WR)3, Z(WK)(WR), Z(WK)2, Z(WK)3, Z(LR)2, Z(LR)3, Z(LK)(LR), Z(LK)2, Z(LK)3. Then, the polypeptide is synthesized by solid phase synthesis, and the polypeptide is identified by mass spectrometry and purified by high performance liquid chromatography, and then subjected to antibacterial activity determination, cytotoxicity determination, cell penetration ability and self-assembly ability determination.
[0042] The amino acid sequences of the modified antimicrobial peptides are as follows (Table 1):
[0043] Trp-Arg-Trp-Arg-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Arg-Trp-Arg-Trp-NH2 (SEQ ID NO: 1), the single letter abbreviation is WRWRCNSKSFCRWRW-NH2, the molecular weight is 2156.5; Trp-Arg-Trp-Arg-Trp-Arg-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Arg-Trp-Arg-Trp-Arg-Trp-NH2 (SEQ ID NO: 2), the single letter abbreviation is WRWRWRCNSKSFCRWRWRW-NH2, the molecular weight is 2841.9; Trp-Arg-Trp-Lys-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Lys-Trp-Arg-Trp-NH2 (SEQ ID NO: NO:3), the single letter abbreviation is WRWKCNSKSFCKWRW-NH2, and the molecular weight is 2101.25;
[0044] Trp-Lys-Trp-Lys-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Lys-Trp-Lys-Trp-NH2 (SEQ ID NO: 4), the single letter abbreviation is WKWKCNSKSFCKWKW-NH2, the molecular weight is 2044.8; Trp-Lys-Trp-Lys-Trp-Lys-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Lys-Trp-Lys-Trp-Lys-Trp-NH2 (SEQ ID NO: 5), the single letter abbreviation is WKWKCNSKSFCKWKW-NH2, the molecular weight is 2044.8; NO:5), the single letter abbreviation is WKWKWKCNSKSFCKWKWKW-NH2, and the molecular weight is 2674; Leu-Lys-Leu-Lys-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Lys-Leu-Lys-Leu-NH2 (SEQ ID NO:6), the single letter abbreviation is LKLKCNSKSFCKLKL-NH2, and the molecular weight is 1752.45; Leu-Lys-Leu-Lys-Leu-Lys-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Lys-Leu-Lys-Leu-Lys-Leu-NH2 (SEQ ID NO:7), the single letter abbreviation is LKLKLKCNSKSFCKLKLKL-NH2, the molecular weight is 2235.4; Leu-Arg-Leu-Lys-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Lys-Leu-Arg-Leu-NH2 (SEQ ID NO:8), the single letter abbreviation is LRLKCNSKSFCKLRL-NH2, the molecular weight is 1808.4; Leu-Arg-Leu-Arg-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Arg-Leu-Arg-Leu-NH2 (SEQ ID NO:9), the single letter abbreviation is LRLRCNSKSFCRLRL-NH2, and the molecular weight is 1864.6; Leu-Arg-Leu-Arg-Leu-Arg-Cys-Asn-Ser-Lys-Ser-Phe-Cys-Arg-Leu-Arg-Leu-Arg-Leu-NH2 (SEQ ID NO:10), the single letter abbreviation is LRLRLRCNSKSFCRLRLRL-NH2, and the molecular weight is 2403.3.
[0045] Table 1 Modified antimicrobial peptide sequences
[0046]
[0047]
[0048] Example 2 Determination of antibacterial activity of modified antimicrobial peptides
[0049] The minimum inhibitory concentration (MIC) of the modified peptide was determined by the standard broth microdilution method. The specific method is as follows:
[0050] The bacteria were cultured in liquid medium until the logarithmic phase, and then the bacterial solution was diluted to 2×10 5 CFU / mL. 100 μL of modified antimicrobial peptides and original antimicrobial peptides (concentrations ranged from 1 to 512 μg / mL) and 100 μL of diluted bacterial solution were mixed in a 96-well plate and cultured in a 37°C incubator for 16 to 20 hours. The OD at 600 nm was measured using an enzyme-labeled instrument. 600 The absorbance value at ) was determined as the MIC. The experiment was repeated 3 times independently, with 3 parallels each time. The results are shown in Table 2.
[0051] Table 2 Minimum inhibitory concentration of modified antimicrobial peptides (μg / mL)
[0052]
[0053] Note: >512μg / mL can be considered invalid. Among them, S.aureus ATCC33591, S.aureus CAU202012P, S.aureus CAU202011H, S.aureus CAU20200JL, these four strains are MRSA. The amino acid sequence of the original antimicrobial peptide Z-d14CFR is: RGCRCNSKSFCVCR-NH2.
[0054] As can be seen from Table 2, this type of modified peptides showed strong antibacterial activity against Escherichia coli, Salmonella or Klebsiella, Staphylococcus aureus, and Streptococcus, while the original antimicrobial peptide Z-d14CFR had no inhibitory effect on MRSA strains and Salmonella.
[0055] Example 3 Determination of time-kill curve of modified antimicrobial peptides
[0056] The time-kill curve of the modified antimicrobial peptide was determined by the colony counting method. The specific method is as follows:
[0057] The bacteria were cultured in liquid culture medium until the logarithmic phase, and then the bacterial solution was diluted with sterile phosphate buffered saline. 100 μL of modified antimicrobial peptides of different concentrations (concentrations ranged from 1×MIC to 4×MIC) were mixed with 100 μL of the diluted bacterial solution to ensure that the bacterial concentration in the mixed solution was 1×10 6 CFU / mL, cultured in a 37°C constant temperature incubator, diluted the bacterial solution to the appropriate concentration at 0, 15, 30, 60, and 120 minutes, and plated, recorded the number of colonies and plotted the results in logarithmic form. Figure 1It can be seen that the modified antimicrobial peptides can kill bacteria in a short time.
[0058] Example 4 Investigation of cytotoxicity of modified antimicrobial peptides
[0059] Mouse macrophages RAW264.7, bovine mammary epithelial cells MAC-T, and African green monkey kidney cells VERO were diluted to 2×10 5 cells / mL, 50 μL of diluted cells were added to a 96-well plate and cultured in a 37°C constant temperature cell culture incubator containing 5% CO2 until they were completely adhered. Then the cell culture medium was removed, and DMEM culture medium containing gradient concentrations of modified antimicrobial peptides was added respectively, and cultured for 24 hours. Then the culture medium was removed again, replaced with fresh DMEM culture medium and 10% CCK-8 solution was added, and the culture plate was placed in a 37°C constant temperature cell culture incubator for 2-4 hours. The 450nm (OD 450 ) Absorbance at . In this experiment, the group not treated with antimicrobial peptides was set as the blank control group, and the group without cells and only containing DMEM and 10% CCK-8 solution was set as the blank group to remove the background. The above experiments were repeated three times independently.
[0060] Cell viability = (OD 450肽处理组 -OD 450空白组 ) / (OD 450空白对照组 -OD 450空白组 )×100%
[0061] The results are as follows Figure 2 As shown, the modified antimicrobial peptide showed no cytotoxicity when the concentration was below 64 μg / mL.
[0062] Example 5 Investigation of the hemolytic activity of modified antimicrobial peptides
[0063] Take an appropriate amount of defibrinated sheep blood, centrifuge at 4°C, 3000g for ten minutes, discard the upper liquid, retain the lower blood cells, then use sterile phosphate buffered saline to resuspend the lower blood cells, centrifuge at 4°C, 3000g for ten minutes, repeat twice to obtain pure blood cells, then take 100μL of blood cell suspension in a 96-well plate. Add 100μL of modified antimicrobial peptide diluted in concentration gradient, and use phosphate buffer containing 0.2% Triton X-100 as a positive control. Place in a 37°C incubator for 1 hour, take out the 96-well plate, centrifuge at 3000g, 4°C for 5 minutes, take the supernatant to a new 96-well plate, and use an enzyme reader to measure 567nm (OD 567 The above experiments were repeated three times independently.
[0064] Hemolysis rate = (OD 567肽处理组 -OD 567空白孔 ) / (OD 567 TritonX-100 -OD 567空白孔 )×100%
[0065] The results are as follows Figure 3 As shown, the engineered antimicrobial peptides showed no hemolytic activity against blood cells.
[0066] Example 6: Bactericidal mechanism of modified antimicrobial peptides
[0067] E. coli CAU201919 or S. aureus 33591 was inoculated into liquid culture medium, cultured overnight at 37°C, and then transferred to new MHB medium until it reached the logarithmic growth phase. The bacterial liquid was centrifuged and the MHB medium was discarded. The remaining bacteria were collected and washed three times with sterile phosphate buffered saline and resuspended with it to an OD of 0. 600 =0.2. The antimicrobial peptides were incubated with bacteria at 37°C for 1h (the control group was not treated with antimicrobial peptides), and then the bacteria were collected by centrifugation, and 600μL of glutaraldehyde (2.5%) was added to resuspend the bacteria and fixed at 4°C overnight. The samples were dehydrated with different concentrations of ethanol (50%, 70%, 90% and 100%). The samples were replaced with a 1:1 (volume ratio) mixture of ethanol and tert-butanol and tert-butanol for 15 minutes respectively. After the samples were dried with a freeze dryer, they were adhered to the sample plate with conductive tape, and a metal film was coated on the surface of the samples with a coating instrument. Finally, images were collected with a scanning electron microscope.
[0068] The results are as follows Figure 4 and Figure 5 As shown, the modified antimicrobial peptides can destroy the bacterial membrane structure and thus kill the bacteria.
[0069] Example 7 Modification of the self-assembly properties of antimicrobial peptides
[0070] The modified antimicrobial peptide was diluted to 32 μg / mL using sterile phosphate buffered saline and allowed to stand at room temperature for 1 hour. 10 μL of the peptide solution was dropped onto a 300-mesh carbon-film copper grid and dried with an infrared lamp. The copper grid was then negatively stained with 1% phosphotungstic acid for 30 seconds, rinsed with distilled water, dried, and observed with a transmission electron microscope.
[0071] The results are as follows Figure 6 As shown, the modified antimicrobial peptides can self-assemble to form a dense nanofiber network structure.
[0072] In summary, the modified antimicrobial peptides provided by the present invention have strong antimicrobial activity against common drug-resistant bacteria such as Escherichia coli, Staphylococcus aureus, Klebsiella, etc., and some of the modified antimicrobial peptides have excellent antimicrobial properties against MRSA and its clinically isolated strains; they have almost no toxicity to macrophages, mammary epithelial cells, and renal epithelial cells, and are non-hemolytic to animal blood cells; the antimicrobial peptides can self-assemble to form nanofiber networks to adhere to bacteria; in addition, the modified antimicrobial peptides mainly exert their antibacterial effects by destroying bacterial membranes, and have application potential in combating bacterial infections such as drug-resistant bacteria.
[0073] Example 8: Stability of modified antimicrobial peptides
[0074] The modified antimicrobial peptide was incubated at different temperatures (37°C, 60°C, 80°C, 90°C and 100°C) for 1 hour, and the MIC values against E. coli ATCC25922 and S. aureus ATCC29213 were measured after the drug solution returned to room temperature.
[0075] The modified antimicrobial peptide was placed in a buffer solution with different pH values (pH 2-12) and incubated for 1 hour, then the pH value of the solution was neutralized to 7.0, and the MIC against E. coli ATCC25922 and S. aureus ATCC29213 was measured.
[0076] The modified antimicrobial peptides were incubated with proteases (pepsin, trypsin, papain, α-chymotrypsin) for 1 hour, during which the pH of the solution was adjusted to the optimal pH for the activity of the protease. Subsequently, the solution was subjected to high temperature treatment to inactivate the protease, and the pH was adjusted to 7.0 to determine the MIC against E. coli ATCC25922 and S. aureus ATCC29213.
[0077] The results are shown in Tables 3, 4 and 5. The modified antimicrobial peptides have good stability in a wide range of temperature and pH environments, and compared with the original antimicrobial peptides, the modified antimicrobial peptides have significantly improved resistance to proteases.
[0078] Table 3 Effect of different temperatures on the stability of antimicrobial peptides
[0079]
[0080]
[0081] Table 4 Effect of different pH values on the stability of antimicrobial peptides
[0082]
[0083] Table 5 Effect of protease on the stability of antimicrobial peptides
[0084]
[0085]
[0086] Note: MIC values > 512 μg / mL can be considered ineffective.
[0087] Although the present invention has been described in detail above with general descriptions and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made based on the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all fall within the scope of protection claimed by the present invention.
Claims
1. An antimicrobial peptide derived from barley worm defensins, characterized in that: The antimicrobial peptide is Z(WR)2, Z(WR)3, Z(WK)(WR), Z(WK)2, Z(WK)3, Z(LR)2, Z(LR)3, Z(LK)(LR), Z(LK)2 or Z(LK)3: Z(WR)2: WRWRCNSKSFCRWRW-NH2; Z(WR)3: WRWRWRCNSKSFCRWRWRW-NH2; Z(WK)(WR):WRWKCNSKSFCKWRW-NH2; Z(WK)2:WKWKCNSKSFCKWKW-NH2; Z(WK)3:WKWKWKCNSKSFCKWKWKW-NH2; Z(LR)2:LKLKCNSKSFCKLKL-NH2; Z(LR)3:LKLKLKCNSKSFCKLKLKL-NH2; Z(LK)(LR):LRLKCNSKSFCKLRL-NH2; Z(LK)2:LRLRCNSKSFCRLRL-NH2; Z(LK)3: LLRLRCNSKSFCRLRLRL-NH2.
2. A nucleic acid molecule encoding the antimicrobial peptide according to claim 1.
3. A biological material containing the nucleic acid molecule according to claim 2, characterized in that: The biological material is recombinant DNA, expression cassette, transposon, plasmid vector, virus vector, engineering bacteria or transgenic cell line.
4. A recombinant microorganism, characterized in that The recombinant microorganism expresses the antimicrobial peptide according to claim 1.
5. Any of the following uses of the antimicrobial peptide according to claim 1: 1) Used to inhibit bacteria; 2) Used for preparing antibacterial agents; 3) Used for preparing preservatives; 4) Used for preparing antibacterial drugs; The bacteria include Gram-negative bacteria and Gram-positive bacteria.
6. The use according to claim 5, characterized in that: The Gram-negative bacteria are selected from Escherichia coli, Salmonella, and Klebsiella.
7. The use according to claim 5, characterized in that: The Gram-positive bacteria are selected from Staphylococcus aureus and Streptococcus.
8. The use according to claim 5, characterized in that: The Gram-positive bacteria is methicillin-resistant Staphylococcus aureus.
Citation Information
Patent Citations
Barley worm natural antibacterial protein and preparation method and application thereof
CN110272474A
Antibacterial peptide defensin derivative as well as prokaryotic expression method and application thereof
CN116262781A
Antibacterial peptide coleoptericin as well as prokaryotic expression method and application thereof
CN116262782A
Surrogate antibodies and methods of preparation and use thereof
US20040018508A1
Cited By
Veterinary antibacterial peptide sustained-release gel as well as preparation method and application thereof
CN119950413A
A veterinary antimicrobial peptide sustained-release gel, its preparation method and its application
CN119950413B
Bacteriostatic agent as well as preparation method and application thereof
CN121513161A
A bacteriostatic agent, its preparation method and application
CN121513161B
Product, system and method of cell cultivation
US12668774B2
